These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17331169)

  • 21. Diagnostic values of surface-enhanced laser desorption/ionization technology for screening of habitual drinkers.
    Sogawa K; Itoga S; Tomonaga T; Nomura F
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S22-6. PubMed ID: 17331162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of a new assay for carbohydrate-deficient transferrin (Biorad %CDT TIA) to monitor abstinence during a treatment outcome study.
    Myrick H; Henderson S; Anton RF
    Alcohol Clin Exp Res; 2001 Sep; 25(9):1330-4. PubMed ID: 11584153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of diagnostic validity of carbohydrate-deficient transferrin and other laboratory markers in chronic ethanol abuse].
    Moravcová E; Bednarík J; Dastych M; Novotná H; Pokora J
    Cas Lek Cesk; 2004; 143(1):39-43. PubMed ID: 15061118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The validity of the laboratory marker combinations DOVER and QUVER to detect physician's diagnosis of at-risk drinking.
    Bentele M; Kriston L; Clement HW; Härter M; Mundle G; Berner MM
    Addict Biol; 2007 Mar; 12(1):85-92. PubMed ID: 17407501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Carbohydrate-deficient transferrin (CDT) is modified by iron status: further reservations regarding the value of a new alcohol marker?].
    Bilzer M; Schmitt UM; Stieber P; Seidel D; Gerbes AL
    Z Gastroenterol; 1999 Sep; 37(9):979-81. PubMed ID: 10522369
    [No Abstract]   [Full Text] [Related]  

  • 26. [Comments on the article by Dastych M. et al: "Diagnostic value of carbohydrate-deficient transferrin, gamma-glutamyltransferase and mean erythrocyte volume as laboratory markers of chronic alcohol abuse"].
    Fingerová H
    Vnitr Lek; 2003 Feb; 49(2):92-4. PubMed ID: 12728573
    [No Abstract]   [Full Text] [Related]  

  • 27. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two-dimensional gel electrophoresis.
    Gravel P; Walzer C; Aubry C; Balant LP; Yersin B; Hochstrasser DF; Guimon J
    Biochem Biophys Res Commun; 1996 Mar; 220(1):78-85. PubMed ID: 8602862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analytical evaluation of a new capillary electrophoresis method for carbohydrate-deficient transferrin measurement.
    Schellenberg F; Girre C; Nalpas B; Plat A; Tome A; Pagès JC
    Clin Chim Acta; 2007 Jul; 382(1-2):48-53. PubMed ID: 17467678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using the EDAC test to monitor abstinence and relapses during outpatient treatment.
    Harasymiw J; Forster I; Bean P
    J Addict Dis; 2005; 24(3):101-13. PubMed ID: 16186087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening trauma patients with the alcohol use disorders identification test and biomarkers of alcohol use.
    Neumann T; Gentilello LM; Neuner B; Weiss-Gerlach E; Schürmann H; Schröder T; Müller C; Haas NP; Spies CD
    Alcohol Clin Exp Res; 2009 Jun; 33(6):970-6. PubMed ID: 19302090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum enzymes and other blood tests used to detect alcohol abuse.
    Kaplan MM
    Trans Am Acad Insur Med; 1993; 76():96-114. PubMed ID: 8101672
    [No Abstract]   [Full Text] [Related]  

  • 32. Biochemical alcohol screening in primary health care.
    Miller PM; Anton RF
    Addict Behav; 2004 Sep; 29(7):1427-37. PubMed ID: 15345274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors affecting %CDT status at entry into a multisite clinical treatment trial: experience from the COMBINE Study.
    Anton RF; Youngblood M
    Alcohol Clin Exp Res; 2006 Nov; 30(11):1878-83. PubMed ID: 17067352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diagnostic tests of alcohol consumption].
    Chrostek L; Szmitkowski M
    Pol Merkur Lekarski; 2002 Aug; 13(74):154-7. PubMed ID: 12420351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying candidate serum biomarkers of exposure to tunicamycins in rats using two-dimensional electrophoresis.
    Penno MA; Bacic A; Colegate SM; Hoffmann P; Michalski WP
    J Proteome Res; 2009 Jun; 8(6):2812-26. PubMed ID: 19317491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [B-PEth and other markers of excessive alcohol us. A comparative study in general practice].
    Bjerre B
    Lakartidningen; 2009 Apr 7-21; 106(15-16):1099-100, 1102-3. PubMed ID: 19492677
    [No Abstract]   [Full Text] [Related]  

  • 37. The Bayesian Alcoholism Test had better diagnostic properties for confirming diagnosis of hazardous and harmful alcohol use.
    Korzec A; de Bruijn C; van Lambalgen M
    J Clin Epidemiol; 2005 Oct; 58(10):1024-32. PubMed ID: 16168348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [CDT: a biological marker of alcohol abuse].
    Crespi V; Andreotta U; Tettamanzi E; Ferrario MM
    Med Lav; 2007; 98(6):466-74. PubMed ID: 18041466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbohydrate-deficient transferrin (CDT) as a marker of alcohol abuse: a critical review of the literature 2001-2005.
    Bortolotti F; De Paoli G; Tagliaro F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Sep; 841(1-2):96-109. PubMed ID: 16725384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Post-mortem stability and redistribution of carbohydrate-deficient transferrin (CDT).
    Rainio J; De Paoli G; Druid H; Kauppila R; De Giorgio F; Bortolotti F; Tagliaro F
    Forensic Sci Int; 2008 Jan; 174(2-3):161-5. PubMed ID: 17475426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.